NEW YORK (GenomeWeb News) – Seattle-based biotech investment and development company Accelerator said today that it has funded the formation of a new microRNA therapeutics company that will develop and market technology licensed exclusively from Nanogen.
 
Mirina, the new entity, will focus on developing therapeutics using an oligonucleotide preparation method called Minor Groove Binder technology developed in Nanogen’s labs.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.